{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:46:14Z","timestamp":1793094374603,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,3,14]],"date-time":"2021-03-14T00:00:00Z","timestamp":1615680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,14]],"date-time":"2021-03-14T00:00:00Z","timestamp":1615680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00432-021-03582-x","type":"journal-article","created":{"date-parts":[[2021,3,14]],"date-time":"2021-03-14T07:02:21Z","timestamp":1615705341000},"page":"3421-3429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine\u2013cisplatin and high dose-intensity MVAC"],"prefix":"10.1007","volume":"147","author":[{"given":"Yongjune","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bumsik","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Mee","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9420-7162","authenticated-orcid":false,"given":"Jae-Lyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,14]]},"reference":[{"key":"3582_CR1","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/s0140-6736(03)13580-5","volume":"361","author":"Advanced Bladder Cancer Meta-analysis Collaboration","year":"2003","unstructured":"Advanced Bladder Cancer Meta-analysis Collaboration (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361:1927\u20131934. https:\/\/doi.org\/10.1016\/s0140-6736(03)13580-5","journal-title":"Lancet"},{"key":"3582_CR2","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","volume":"71","author":"J Alfred Witjes","year":"2017","unstructured":"Alfred Witjes J et al (2017) Updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71:462\u2013475. https:\/\/doi.org\/10.1016\/j.eururo.2016.06.020","journal-title":"Eur Urol"},{"key":"3582_CR3","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","volume":"395","author":"A Birtle","year":"2020","unstructured":"Birtle A et al (2020) Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet 395:1268\u20131277. https:\/\/doi.org\/10.1016\/S0140-6736(20)30415-3","journal-title":"Lancet"},{"key":"3582_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"3582_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/JU.0000000000000172","volume":"202","author":"N Chakiryan","year":"2019","unstructured":"Chakiryan N, Martinez A, Gao L, Liu JJ, Amling C, Garzotto M, Kopp RP (2019) Optimizing the sequence of chemotherapy for upper tract urothelial carcinoma with clinically positive regional lymph nodes. J Urol 202:76\u201382. https:\/\/doi.org\/10.1097\/JU.0000000000000172","journal-title":"J Urol"},{"key":"3582_CR6","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","volume":"198","author":"SS Chang","year":"2017","unstructured":"Chang SS et al (2017) Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline. J Urol 198:552\u2013559. https:\/\/doi.org\/10.1016\/j.juro.2017.04.086","journal-title":"J Urol"},{"key":"3582_CR7","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/jco.2013.52.4785","volume":"32","author":"TK Choueiri","year":"2014","unstructured":"Choueiri TK et al (2014) Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol 32:1889\u20131894. https:\/\/doi.org\/10.1200\/jco.2013.52.4785","journal-title":"J Clin Oncol"},{"key":"3582_CR8","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1200\/JCO.2019.37.15_suppl.4506","volume":"37","author":"TW Flaig","year":"2019","unstructured":"Flaig TW et al (2019) SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer. J Clin Oncol 37:4506\u20134506. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.4506","journal-title":"J Clin Oncol"},{"key":"3582_CR9","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859\u2013866. https:\/\/doi.org\/10.1056\/NEJMoa022148","journal-title":"N Engl J Med"},{"key":"3582_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.eururo.2014.03.003","volume":"66","author":"JJ Leow","year":"2014","unstructured":"Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J (2014) A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 66:529\u2013541. https:\/\/doi.org\/10.1016\/j.eururo.2014.03.003","journal-title":"Eur Urol"},{"key":"3582_CR11","unstructured":"National Cancer Institute (2010) Common Terminology Criteria for Adverse Events (CTCAE):Version 4.03; 2020. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_4.03.xlsx. Accessed 1 July 2020"},{"key":"3582_CR12","unstructured":"National Comprehensive Cancer Network (2020) Bladder Cancer (version 6.2020); 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf. Accessed 15 Jan 2021"},{"key":"3582_CR13","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1001\/jamaoncol.2018.3542","volume":"4","author":"CC Peyton","year":"2018","unstructured":"Peyton CC et al (2018) Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer. JAMA Oncol 4:1535\u20131542. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3542","journal-title":"JAMA Oncol"},{"key":"3582_CR14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"C Pfister","year":"2021","unstructured":"Pfister C et al (2021) Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG\/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur Urol 79:214\u2013221. https:\/\/doi.org\/10.1016\/j.eururo.2020.08.024","journal-title":"Eur Urol"},{"key":"3582_CR15","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1200\/jco.2001.19.10.2638","volume":"19","author":"CN Sternberg","year":"2001","unstructured":"Sternberg CN et al (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19:2638\u20132646. https:\/\/doi.org\/10.1200\/jco.2001.19.10.2638","journal-title":"J Clin Oncol"},{"key":"3582_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","volume":"42","author":"CN Sternberg","year":"2006","unstructured":"Sternberg CN et al (2006) Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42:50\u201354. https:\/\/doi.org\/10.1016\/j.ejca.2005.08.032","journal-title":"Eur J Cancer"},{"key":"3582_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00345-015-1636-y","volume":"34","author":"EE van de Putte","year":"2016","unstructured":"van de Putte EE et al (2016) Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine\/cisplatin. World J Urol 34:157\u2013162. https:\/\/doi.org\/10.1007\/s00345-015-1636-y","journal-title":"World J Urol"},{"key":"3582_CR18","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H von der Maase","year":"2000","unstructured":"von der Maase H et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068\u20133077","journal-title":"J Clin Oncol"},{"key":"3582_CR19","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.juro.2017.12.062","volume":"199","author":"H Zargar","year":"2018","unstructured":"Zargar H et al (2018) Neoadjuvant dose dense MVAC versus gemcitabine and cisplatin in patients with cT3\u20134aN0M0 bladder cancer treated with radical cystectomy. J Urol 199:1452\u20131458. https:\/\/doi.org\/10.1016\/j.juro.2017.12.062","journal-title":"J Urol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03582-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03582-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03582-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T13:11:09Z","timestamp":1633007469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03582-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,14]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["3582"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03582-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-164451\/v1","asserted-by":"object"}]},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,14]]},"assertion":[{"value":"20 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no relevant conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors consent to publish this study in J Cancer Res Clin Oncol.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IRB of Asan Medical Center reviewed and approved this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}